<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04276220</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-178-19</org_study_id>
    <nct_id>NCT04276220</nct_id>
  </id_info>
  <brief_title>Prevalence of Wild-Type Transthyretin Cardiac Amyloidosis Among Patients Undergoing Carpal Tunnel Release Surgery - A Prospective Study</brief_title>
  <official_title>Prevalence of Wild-Type Transthyretin Cardiac Amyloidosis Among Patients Undergoing Carpal Tunnel Release Surgery - A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steen Hvitfeldt Poulsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital Skejby</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients above the age of 60 will be recruited at their carpal tunnel release surgery.
      Biopsies will be taken from the wrist and examined for the presence of amyloid protein. A
      amyloid-positive biopsy will refer the patients for cardiac examination.

      If the result of the cardiac examination is suspected cardiac amyloidosis, the patient will
      be referred for a diagnostic TC99-DPD scintigraphy. If the scintigraphy is positive, the
      patient will be referred for right heart catherization (RHC) and an exercise test.

      Myocardial biopsies will be taken at the RHC and examined with electron microscopy and high
      resolution respirometry.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of wild-type transthyretin cardiac amyloidosis</measure>
    <time_frame>Through study completion, 2 years.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Transthyretin Amyloidosis</condition>
  <condition>Transthyretin Cardiac Amyloidosis</condition>
  <condition>Wild-Type Transthyretin-Related (ATTR)Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Tenosynovial Biopsy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tenosynovial biopsy</intervention_name>
    <description>Tenosynovial biopsy taken from the wrist at the carpal tunnel release surgery.</description>
    <arm_group_label>Tenosynovial Biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males above 65 years of age, females above 75 years of age.

          -  Scheduled idiopathic carpal tunnel release surgery.

          -  Informed written consent.

        Exclusion Criteria:

          -  Operation by other indication, e.g.

          -  Fracture

          -  Ganglion

          -  Known amyloidosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bertil Ladefoged</last_name>
    <phone>+45 40 92 72 45</phone>
    <email>berlad@rm.dk</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital Skejby</investigator_affiliation>
    <investigator_full_name>Steen Hvitfeldt Poulsen</investigator_full_name>
    <investigator_title>Professor, DMSc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

